Core Insights - Senseonics Holdings, Inc. specializes in long-term, implantable continuous glucose monitoring systems for diabetes management, with its flagship product being the Eversense CGM System [1] - The company faces competition from other medical technology and biotechnology firms in the market [1] Financial Performance - Senseonics has a Weighted Average Cost of Capital (WACC) of 8.89% and a Return on Invested Capital (ROIC) of -66.62%, resulting in a ROIC to WACC ratio of -7.50, indicating it is not generating returns above its cost of capital [2][6] - Compared to its peers, Senseonics has a better ROIC to WACC ratio than Bionano Genomics, which has a WACC of 4.27% and a ROIC of -64.06, leading to a ratio of -15.00 [3][6] - Zomedica Corp. has a WACC of 9.37% and a ROIC of -70.67%, resulting in a ROIC to WACC ratio of -7.54, which is slightly worse than Senseonics [4][6] - Castor Maritime Inc. stands out with the highest ROIC to WACC ratio of -0.76 among peers, indicating relatively better capital efficiency despite all companies analyzed generating returns below their cost of capital [5][6]